I saw the article that you coauthored on the digital breast imaging forum at SCAR ("Breast imagers come out swinging against digital mammography vendors," diagnosticimaging.com/scar2005/, June 7, 2005. An expanded version appears in the SCAR Conference Reporter, this issue, page 54). I am very happy that you were there and interested in digital mammography. Also, I am pleased that you described the struggles we are having on the clinical side so accurately.
I saw the article that you coauthored on the digital breast imaging forum at SCAR ("Breast imagers come out swinging against digital mammography vendors," diagnosticimaging.com/scar2005/, June 7, 2005. An expanded version appears in the SCAR Conference Reporter, this issue, page 54). I am very happy that you were there and interested in digital mammography. Also, I am pleased that you described the struggles we are having on the clinical side so accurately.
However, I feel that your article has misrepresented the tone of the meeting. You state that the vendors were cornered-actually, they were not. Everyone was invited to come, and the agenda was widely available to all, including the vendors, who supported the forum and its goals with time and funding. The vendors have been amazingly willing to help us fix the issues that we are facing. As we continue through this process, factual journalism is important to publicize the developments, but sensationalized coverage just serves to disrupt the fragile bridges that we are all trying to form in order to solve our problems. I feel that your article, while containing some facts, has partially undone some of the partnership that we are working so hard to form.
-Rita Zuley, M.D.
Elizabeth Wende Breast Clinic
Rochester, NY
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.